What this site is. What it is not.

About this site

Pharmacy Retatrutide reads the peer-reviewed research literature on retatrutide and reports it back forensically. No clinic stands behind it and no clinician is on staff; it gives no medical advice, and it makes, stocks, and sells nothing. Its work is a reading of published science.

The domain name includes the word pharmacy. This is a search-positioning choice, not a claim about our services. We are not a pharmacy. We do not dispense, compound, or supply any pharmaceutical or research-labeled product. A pharmacist has not reviewed this content in a clinical capacity. The word pharmacy in the domain name is editorial framing — occupying the searcher's intent around availability and sourcing in order to deliver accurate, cited information about retatrutide's actual status: investigational, unapproved, not commercially available.

This site is built around the liver-MASLD angle of the retatrutide literature — the Phase 2a substudy in which 82.4% liver-fat reduction was measured at 24 weeks is the single most striking published finding in the retatrutide record, and it is underrepresented in community discussion relative to body-weight outcomes. This site foregrounds it.

What we publish and what we do not

We publish:

• Summaries of published Phase 1 and Phase 2 clinical trial findings, with full citations.
• Mechanistic readings of how retatrutide works at the receptor level.
• Labeled accounts of community-reported effects, clearly marked as anecdotal and unverified.
• Documented safety cautions grounded in mechanism and published trial data.
• Direct answers to common questions about retatrutide's regulatory status and availability.

We do not publish:

• Dosing instructions or reconstitution protocols.
• Sourcing information or vendor referrals for any retatrutide product.
• Medical advice of any kind.
• Predictions about FDA approval timelines not supported by public regulatory filings.
• Claims that retatrutide treats, cures, or prevents any condition — the correct framing is that trials have studied it for these conditions and measured specific outcomes.

Every quantitative claim on this site is cited to a specific publication. If a claim is not in the cited literature, it is not on this site.

Editorial standards

The accuracy guard for retatrutide content on this site is strict:

Retatrutide is investigational — not approved anywhere. It is never described as an approved drug or available product.

Trial results are study-attributed and specific: "In a 48-week Phase 2 trial, 12 mg produced a mean -24.2% body-weight change" — not "retatrutide causes 24% weight loss."

Community reports are labeled anecdotal, not clinical evidence — every time, in the section where they appear.

Competitor brand names do not appear on this site. Generic compound names (semaglutide, tirzepatide) are used only in legitimate comparative context.

The "GLP-3" misnomer is corrected, not propagated: retatrutide is a GIP/GLP-1/glucagon triagonist; there is no GLP-3 receptor.

This site is a reading of the record as published. The record will change as Phase 3 results emerge. When the published literature updates, this site will be updated.